Diagnosis and treatment of heart failure need new approaches; natriuretic peptides may be simple, reliable diagnostic and outcome variables;Utredning och behandling av hjärtsvikt söker nya vägar: Natriuretiska peptider kan bli säkert och enkelt mått i diagnostik och behandling

Lakartidningen

Volumn , Issue 47, 1998, Pages 5311-5315

  Lindstedt, Göran ^a,h   Bergh, Claes Håkan ^b   Caidahl, Kenneth ^b   Ekman, Rolf ^c   Fagerberg, Björn ^d   Isgaard, Jörgen ^e   Lundberg, Per Arne ^a   Swedberg, Karl ^f   Wallén, Thomas ^g  

^a Institutionen for Laboratoriemedicin   (Sweden)

^b Bagge Sahlgrenska U   (Sweden)

^c Institutionen Klinisk Neurovetenskap   (Sweden)

^d Sahlgrenska U   (Sweden)

^e Sahlgrenska U   (Sweden)

^f Samtliga Norrlands U   (Sweden)

^g Sahlgrenska U   (Sweden)

^h Institute of Laboratory Medicine   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; NATRIURETIC FACTOR;

AMINO ACID SEQUENCE; BRAIN; CHEMISTRY; CONGESTIVE HEART FAILURE; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; HUMAN; METABOLISM; MOLECULAR GENETICS; PROGNOSIS; REVIEW; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AMINO ACID SEQUENCE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; BRAIN; DIAGNOSIS, DIFFERENTIAL; ENDOTHELIUM, VASCULAR; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MOLECULAR SEQUENCE DATA; NATRIURETIC AGENTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032544896     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rydén L. Vård vid hjärtsvikt kan bli bättre. Läkartidningen 1997; 94: 2369-72.
2. Johansson Gunilla. Visst kan vård vid hjärtsvikt bli bättre! Läkartidningen 1997; 94: 4445.
3. Rydén L. Bättre hjärtsviktsvård till lägre kostnad. Effektiva vårdprogram frigör resurser. Läkartidningen 1998; 95: 2780-1.
4. Andersson F, Rydén-Bergsten T. Hjärtsvikt kostar! Klok läkemedelsanvändning kan kapa antalet dyra sjukhusdagar. Läkartidningen 1998; 95: 2828-30.
5. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995; 16: 741-51.
6. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJV. The prevalence of left ventricular diastolic filling abnormalities in patients with suspected heart failure. Eur Heart J 1997; 18: 981-4.
7. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
8. Dickstein K. Natriuretic peptides in detection of heart failure [editorial]. Lancet 1998; 351: 4.
9. Wallén T. Natriuretic peptides in the elderly. Implications for morbidity and mortality [dissertation]. Göteborg: Göteborgs universitet, 1997.
10. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-9.
11. Murdoch DR, Byrne J, Morton JJ, McDonagh TA, Robb SD, Clements S et al. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart 1997; 78: 594-7.
12. Omland T, Aakvaag A, Bonarjee VVS, Caidahl K, Lie RT, Nilsen DWT et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and longterm survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963-9.
13. Cowie MR, Struthers AD, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
14. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJV et al. Symptomatic and asymptomatic leftventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829-33.
15. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
16. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure [guidelines]. Eur Heart J 1997; 18: 736-53.
17. Struthers AD. Rationalizing the heart failure trials: from theory to practice. Eur Heart J 1997; 18 suppl E: E5-E8.
18. Murdoch DR, McDonagh TA, Blue L, Morton JJ, McMurray JJV, Dargie HJ. Optimising the treatment of chronic heart failure: titration of vasodilator therapy according to plasma brain natriuretic peptide concentration [abstract P 1681]. Eur Heart J 1997; 18 suppl: 292.
19. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998; 19: 696-710.